Articles related to PRECISION MEDICINE

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

Sotorasib treatment in two patients with severe KRAS G12C-driven arteriovenous malformations resulted in rapid symptomatic improvement and sustained reduction in malformation volume over 24 months.

Tempus AI, leveraging one of the world’s largest clinical and molecular oncology data libraries, files for an IPO, aiming to raise substantial funds to support its mission of advancing AI-powered precision medicine.

In a recent phase 3 trial, asciminib has shown superior efficacy and safety in newly diagnosed chronic myeloid leukemia patients, achieving a higher major molecular response rate at week 48 compared to traditional tyrosine kinase inhibitors.